GSK PLC (GSK)
33.69
+0.34
(+1.02%)
USD |
NYSE |
Nov 21, 16:00
33.69
0.00 (0.00%)
After-Hours: 20:00
GSK Enterprise Value: 84.49B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 84.49B |
| November 19, 2024 | 84.72B |
| November 18, 2024 | 85.19B |
| November 15, 2024 | 84.49B |
| November 14, 2024 | 86.61B |
| November 13, 2024 | 88.08B |
| November 12, 2024 | 88.92B |
| November 11, 2024 | 90.61B |
| November 08, 2024 | 90.49B |
| November 07, 2024 | 91.24B |
| November 06, 2024 | 89.69B |
| November 05, 2024 | 91.98B |
| November 04, 2024 | 91.88B |
| November 01, 2024 | 91.69B |
| October 31, 2024 | 91.45B |
| October 30, 2024 | 91.96B |
| October 29, 2024 | 94.33B |
| October 28, 2024 | 93.73B |
| October 25, 2024 | 93.00B |
| October 24, 2024 | 93.45B |
| October 23, 2024 | 93.94B |
| October 22, 2024 | 93.98B |
| October 21, 2024 | 94.30B |
| October 18, 2024 | 95.10B |
| October 17, 2024 | 95.94B |
| Date | Value |
|---|---|
| October 16, 2024 | 96.45B |
| October 15, 2024 | 95.94B |
| October 14, 2024 | 96.28B |
| October 11, 2024 | 95.67B |
| October 10, 2024 | 96.45B |
| October 09, 2024 | 98.55B |
| October 08, 2024 | 94.02B |
| October 07, 2024 | 95.26B |
| October 04, 2024 | 95.65B |
| October 03, 2024 | 94.73B |
| October 02, 2024 | 96.94B |
| October 01, 2024 | 98.67B |
| September 30, 2024 | 99.85B |
| September 27, 2024 | 99.92B |
| September 26, 2024 | 100.31B |
| September 25, 2024 | 99.62B |
| September 24, 2024 | 100.47B |
| September 23, 2024 | 100.23B |
| September 20, 2024 | 100.11B |
| September 19, 2024 | 101.78B |
| September 18, 2024 | 103.43B |
| September 17, 2024 | 103.70B |
| September 16, 2024 | 105.71B |
| September 13, 2024 | 104.61B |
| September 12, 2024 | 104.82B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
76.06B
Minimum
Sep 30 2022
139.10B
Maximum
Dec 20 2019
107.91B
Average
110.43B
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 221.25B |
| Pfizer Inc | 198.27B |
| Sanofi SA | 136.14B |
| Moderna Inc | 7.348B |
| Autolus Therapeutics PLC | 88.07M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -75.47M |
| Revenue (Quarterly) | 10.43B |
| Total Expenses (Quarterly) | 10.18B |
| EPS Diluted (Quarterly) | -0.0364 |
| Gross Profit Margin (Quarterly) | 70.08% |
| Profit Margin (Quarterly) | -0.72% |
| Earnings Yield | 4.57% |
| Operating Earnings Yield | 8.16% |
| Normalized Earnings Yield | 5.351 |